



Support for an Early Biotech

初期創薬スタートアップへの支援



Thu 7-9pm, Oct. 9 in JST



TECH HUB YOKOHAMA



EN



Food/Drink



Free

Panelists



Shu Konakahara
AbbVie Ventures



Hikaru Saito
Saisei Ventures



Ariane Doischer
BioM



Kiyoko Mashio
Institute of Science Tokyo



Susan Chase
BioLabs



Hiroshi Atsumi
iCONM with BioLabs
(Moderator)



Register
here!



TECH
HUB
YOKOHAMA



iCONM
In collaboration with
biolabs

BioJapan 2025

創薬スタートアップ初期には、知識や設備、資金やネットワークがとても重要だゾ。このイベントでは、設立初期の創薬スタートアップの支援にはどのような支援があるのか、どのような組織がいるのかを知れる、創薬スタートアップ初期～中期・VC・大学産学連携・他スタートアップ支援者の方向けのイベントになるゾ！

Details(EN)

Date: Thursday 7:00-9:00pm, October 9th, 2025

Title: Support for an Early Biotech

Venue: TECH HUB YOKOHAMA

Summary : Starting a drug discovery startup? In the early stages, knowledge, facilities, funding, and networks matter more than ever. This event is all about discovering what kind of support is out there for early-stage startups—who provides it and how to access it. It's a great opportunity for founders, mid-stage teams, VCs, university-industry partners, and other startup supporters to connect and learn!

Purpose : This program brings together drug discovery entrepreneurs to share knowledge and experiences, learn how to secure funding, and build strong networks to kick-start their startups.

Program :

- 7:00- Greeting
- 7:10- Self-intro
- 7:25- Panel Discussion
- 8:00- Q&A
- 8:20- Networking

詳細内容 (JP)

Date: Thursday 7:00-9:00pm, October 9th, 2025

Title: 初期創薬スタートアップへの支援

Venue: TECH HUB YOKOHAMA

概要：創薬スタートアップ初期には、知識や設備、資金やネットワークがとても重要となります。このイベントでは、設立初期の創薬スタートアップの支援にはどのような支援があるのか、どのような組織がいるのかを知れる、創薬スタートアップ初期～中期・VC・大学産学連携・他スタートアップ支援者の方向けのイベントになります！

目的：創薬系起業家が、スタートアップを始めるための知識や経験を共有し、資金をどのように調達するべきかを知り、ネットワークを構築していくことを目指します。

プログラム：

- 7:00- 挨拶
- 7:10- パネリスト自己紹介
- 7:25- パネルディスカッション
- 8:00- Q&A
- 8:20- ネットワーキング

Panelist



Shu Konakahara
AbbVie Ventures

Shu Konakahara, Ph.D. is Manager of JAPAC Strategic Planning & Evaluation at AbbVie GK and Scientist in Residence at AbbVie Ventures. He has 15+ years of experience in academia, biotech, and pharma, specializing in antibody discovery, early clinical development in Asia, and precision medicine. He is skilled in joint research negotiation, business development due diligence, leadership, and stakeholder communication. He quickly adapts to new areas, makes timely decisions, and is passionate about advancing innovative science and bridging pharma with the biotech community.



Hikaru Saito
Saisei Ventures

The career started with a Ph.D. on multidrug resistance under Prof. Ishikawa, followed by compound screening with Prof. Nureki and Nihon Chemiphar, leading to a granted patent. At Astellas, worked as a scientist in formulation, process development, and GMP manufacturing, then on recombinant fibrinogen from transgenic silkworms, which informed later work in cell and gene therapy. After 6 years as a scientist, transitioned into business development at Astellas Innovation Management and later Astellas Venture Management in Silicon Valley. Led global deal processes in RNA, cell and gene therapy, due diligence, financings, fund investments, and partnerships with US/EU VCs. Motivated by curiosity in emerging science and building innovative companies to transform healthcare.



Ariane Doischer
BioM

Ariane Doischer is International Relations Manager at BioM Biotech Cluster Development GmbH, leading international project management and business development to strengthen the biotech ecosystem in Bavaria and beyond. She previously held roles at Sana Kliniken in international marketing and business development, and at Arthrex in corporate sustainability. Earlier, she gained experience in international trade and development at NürnbergMesse, trAIDe GmbH, GIZ, and the German-Costa Rican Chamber of Commerce. She is IPMA Level D certified in project management, skilled in biotechnology, drug development, and clinical studies, and fluent in English, Spanish, and Italian.



Kiyoko Mashio
(Institute of Science Tokyo)

Kiyoko Mashio is Professor and Deputy Director of the Innovation Design Organization at the Institute of Science Tokyo, overseeing the Greater Tokyo Innovation Ecosystem (GTIE). After starting her career at a major domestic megabank, she worked in financial market research at domestic and international investment banks. Her role at a government-affiliated institution investing in university startups shifted her focus toward supporting entrepreneurship and innovation ecosystems. She joined the Institute in 2022 and now advances the startup ecosystem through the GAP Fund Program, supporting researchers in commercializing their work and bridging academia with entrepreneurship.



Susan Chase
BioLabs

Susan Chase is Senior Vice President of Business Development at Bio Innovation Labs ("Biolabs"), the leading global co-working lab platform for early-stage biotech startups. She drives partnerships with pharma, investors, academia, and municipalities to create innovation spaces worldwide. Previously, she directed collaborative programs at The Boston Consortium and MASCO and built expertise in operations and strategy through earlier roles in real estate and risk management. She is recognized for strengths in strategic partnerships, program management, and fostering innovation across stakeholders.